The emerging role of immunotherapy in the treatment of non-melanoma skin cancers

Nature Clinical Practice Oncology

Volumn 2, Issue 7, 2005, Pages 326-327

  Sauder, Daniel N ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; FLUOROURACIL; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOMODULATING AGENT; TOLL LIKE RECEPTOR;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BURNING SENSATION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; DRUG MECHANISM; ERYTHEMA; HUMAN; IMMUNOMODULATION; MELANOMA; MONOTHERAPY; PAIN; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION; ARTICLE; IMMUNOLOGY; IMMUNOTHERAPY; SKIN TUMOR;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOTHERAPY; SKIN NEOPLASMS;

EID: 23844549647     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0226     Document Type: Review

References (12)

1. Baron ED and Stevens SR (2002) Sunscreens and immune protection. Br J Dermatol 146: 933-937
2. American Cancer Society (online 2005) Cancer facts and figures 2003 [http://www.cancer.org/docroot/STT/ stt_0_2003.asp?sitearea=STT&level=l] (accessed 3 June 2005)
3. Chuang T and Ulevitch RJ (2001) Identification of hTLR10: A novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518: 157-161
4. Gaspari AA and Sauder DN (2003) Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 29: 1027-1034
5. Schön M et al. (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95: 1138-1149
6. Berman B et al. (2003) Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 149 (Suppl 66): 59-61
7. Torres A et al. (2004) 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Moh's micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg 30 (Pt 1): 1462-1469
8. Geisse J et al. (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50: 722-733
9. Shumack S et al. (2002) Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: Comparison of dosing regimens. Arch Dermatol 138: 1165-1171
10. Majewski S et al. (2005) Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 44: 14-19
11. Jeffes EW Jr and Tang EH (2000) Actinic keratoses. Current treatment options. Am J Clin Dermatol 1: 167-179
12. Sauder DN and Mofid MZ (2005) Topical immunotherapy: What's new. Dermatol Clin 23: 245-258